HCPLive Network

Medicare Beneficiaries Use More Brand-Name Drugs Than Veterans Affairs

TUESDAY, June 11 (HealthDay News) -- Compared to seniors with diabetes treated through Veterans Affairs (VA), Medicare beneficiaries with diabetes use two to three times more brand-name drugs, driving up costs substantially, according to research published online June 11 in the Annals of Internal Medicine.

Walid F. Gellad, MD, MPH, from the Veterans Affairs Pittsburgh Healthcare System, and colleagues retrospectively analyzed data from 1,061,095 Medicare Part D beneficiaries and 510,485 veterans aged 65 years or older with diabetes. The authors sought to identify the percentage of patients taking oral hypoglycemics, statins, and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) who filled brand-name drug prescriptions and percentage of patients taking long-acting insulins who filled analogue prescriptions.

The researchers found that brand-name drug use in Medicare was two to three times that in the VA (oral hypoglycemics, 35.3 versus 12.7 percent; statins, 50.7 versus 18.2 percent; ACE inhibitors or ARBs, 42.5 versus 20.8 percent; and insulin analogues, 75.1 versus 27.0 percent). From the fifth to the 95th percentiles, adjusted hospital referral region (HRR)-level brand-name statin use ranged from 41.0 to 58.3 percent in Medicare and 6.2 to 38.2 percent in the VA. For each drug group there was lower brand-name drug use for the 95th-percentile HRR in the VA compared to the 5th-percentile HRR in Medicare. Medicare spending would have been $1.4 billion less in this population if brand-name drug use had matched that of the VA.

"Medicare beneficiaries with diabetes use two to three times more brand-name drugs than a comparable group within the VA, at substantial excess cost," the authors write.

Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Glucose intolerances may be linked to non-caloric artificial sweeteners, according to research published in Nature.
Research teams examining the safety and efficacy of zanamivir and oseltamivir for influenza treatment concluded they are not as effective as popularly believed.
HDL cholesterol may have atheroprotective qualities, according to a report from The New England Journal of Medicine.
More Reading